Denali Therapeutics Inc. (DNLI) Tops Q2 EPS by 8c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.59), $0.08 better than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• JPMorgan Upgrades Graphic Packaging Holding Company (GPK) to Overweight
• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Jefferies Starts Frencken Group Ltd. (FRKN:SP) at Buy